SCHEMBL4462887

SCHEMBL4462887

CC(C)(C)c1cc(O)cc2c1OC1(CCC1)CC2

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 6/20 0.44
NR1I2 O75469 3/20 0.33
LMNA P02545 2/20 0.33
ALDH1A1 P00352 2/20 0.33
ALOX15 P16050 2/20 0.33
CYP2C9 P11712 1/20 0.33
MIF P14174 1/20 0.33
TYR P14679 1/20 0.33
HTT P42858 1/20 0.33
NFE2L2 Q16236 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ALOX5 P09917 5/20 0.33
KDM4E B2RXH2 1/20 0.31
CYP1A2 P05177 1/20 0.31
MAPT P10636 1/20 0.31
ATP2A2 P16615 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ATP2A3 Q93084 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11836367 0.84 AKT1 (0.47) AKT1NR1I2LMNAALDH1A1ALOX15
SCHEMBL25826782 0.74 ALDH1A1 (0.35) AKT1NR1I2LMNAALDH1A1ALOX15
SCHEMBL4462820 0.74 ALOX15 (0.41) NR1I2LMNAALDH1A1ALOX15CYP2C9
SCHEMBL4466778 0.69 AKT1 (0.53) AKT1LMNAALOX5
SCHEMBL15936419 0.69 LMNA (0.36) AKT1NR1I2LMNAALDH1A1ALOX15
SCHEMBL4462428 0.68 ALDH1A1 (0.35) ALDH1A1CYP2C9TYRKDM4ECYP1A2
SCHEMBL4475359 0.67 AKT1 (0.49) AKT1
SCHEMBL19296761 0.66 ALDH1A1 (0.39) NR1I2LMNAALDH1A1ALOX15CYP2C9
SCHEMBL13423096 0.66 MALT1 (0.33) AKT1NFE2L2
SCHEMBL11650116 0.64 AKT1 (0.38) AKT1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 AKT1 1241/4885NR1I2 295/4885LMNA 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.